Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrocodone + doxapram
- Development stage
- Phase 1
- Lead developer
- Quivive Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QEV-817 is an investigational, immediate-release oral suspension combination of **hydrocodone bitartrate** and **doxapram hydrochloride** developed by **Quivive Pharma**. Hydrocodone is a well-established opioid analgesic that acts as an agonist at the mu-opioid receptor to treat pain. Doxapram is a respiratory stimulant that, when included at sub-therapeutic doses in this formulation, is intended to act as a safety mechanism by counteracting opioid-induced respiratory depression (OIRD) resulting from accidental or intentional overdose. The product is being developed via the FDA's 505(b)(2) regulatory pathway and is currently in Phase 1 clinical trials (NCT06585163) to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.
- Other names
- hydrocodone bitartrate + doxapram hydrochloride
02
Targets
DOR (Opioid Receptor Delta 1)KCNK3 (Two-pore domain potassium channel subfamily K member 3 (TASK-3))KOR (Kappa opioid receptor)MOR (Mu opioid receptor)KCNK2 (Potassium channel subfamily K member 2)KCNK9 (Potassium channel subfamily K member 9)
Beyond the preview
Go deeper on hydrocodone + doxapram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrocodone + doxapram.